12230 El Camino Real
Suite 230
San Diego, CA 92130
United States
858 434 1113
https://www.oncternal.com
Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 27
Name | Title | Pay | Exercised | Year born |
---|---|---|---|---|
Dr. James B. Breitmeyer M.D., Ph.D. | President, CEO & Director | 881.36k | N/A | 1954 |
Dr. Rajesh Krishnan Ph.D. | Chief Technical & Scientific Officer | N/A | N/A | 1973 |
Mr. Chase C. Leavitt | General Counsel & Secretary | N/A | N/A | 1982 |
Mr. Pablo Urbaneja | Senior Vice President of Corporate Development | N/A | N/A | N/A |
Ms. Anita Wiseth | Senior Vice President of Human Resources | N/A | N/A | N/A |
Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial. It is also developing ONCT-808, a chimeric antigen receptor T-cells (CAR-T), which is in Phase 1/2 clinical trial for the treatment of hematologic malignancies and solid tumors, as well as targets ROR1; and ONCT-534, a dual-action androgen receptor inhibitor product candidate in preclinical development for the treatment of castration-resistant prostate and other androgen receptor-driven cancers. The company has license agreements with the Regents of the University of California; Georgetown University; The University of Texas MD Anderson Cancer Center; Shanghai Pharmaceutical (USA) Inc.; and University of Tennessee Research Foundation. Oncternal Therapeutics, Inc. is headquartered in San Diego, California.
Oncternal Therapeutics, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.